

Substitute for PTO/SB/O&A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/525,610
				Filing Date	March 24, 2006
				First Named Inventor	Kevin J. Williams
				Group Art Unit	1643
				Examiner Name	Alana M. Harris
				Attorney Docket Number Customer No.	W1107/20010 03000
Sheet	1	of	13		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	AA	4,820,505		Ginsberg, et al.	04/11/1989	
	AB	4,610,960		Mosher	09/09/1986	
	AC	5,686,583		Bosslet, et al.	11/11/1997	
	AD	5,256,538		Aiken, et al.	10/26/1993	
	AE	5,192,744		Bouck, et al.	03/09/1993	
	AF	6,239,110		Eyal, et al.	05/29/2001	
	AG	5,654,277		Eyal, et al.	08/05/1997	
	AH	5,840,692		Deutsch, et al.	11/24/1998	
	AI	6,051,549		Roberts, et al.	04/18/2000	
	AJ	5,753,517		Brooks, et al.	05/19/1998	
	AK	5,840,507		Fruehauf	11/24/1998	
	AL	6,339,062		Williams, et al.	01/15/2002	
	AM	5,750,502		Jessell, et al.	05/12/1998	
	AN	2001/0041670		Simantov, et al.	11/15/2001	
	AO	2002/0197697		Abdelouahed, et al.	12/26/2002	
	AP	2003/0180295		Tuszynski, et al.	09/25/2003	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
	AQ		WO 01/05968	Tuszynski, et al.	01/25/2001	
	AR		International Search Report PCT/ US03/260 23	Williams	08/20/2003	

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AS	Baenziger NL <i>et al.</i> Isolation and properties of a thrombin-sensitive protein of human platelets. J. Biol. Chem., 1972. 247:2723-2731.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	2	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

AT	Lawler JW <i>et al.</i> Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem., 1978. 253(23):8609-8616. (Abstract only)	
AU	Wallinder L <i>et al.</i> Rapid removal to the liver of intravenously injected lipoprotein lipase. Biochem. Biophys. Acta, 1979. Oct 26; 575(1):166-173. (Abstract only)	
AV	Margossian SS <i>et al.</i> Physical characterization of platelet thrombospondin. J. Biol. Chem., 1981. 256(14):7495-7500.	
AW	Saglio SD <i>et al.</i> Use of a radioimmunoassay to quantify thrombospondin. Blood, 1982. Jan; 59(1):162-166. (Abstract only)	
AX	Mosher DF <i>et al.</i> Synthesis and secretion of thrombospondin by cultured human endothelial cells. J. Cell Biol., 1982. 93(2):343-348.	
AY	Dawes J <i>et al.</i> A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. Thromb. Res., 1983. March 15; 29:569-581.	
AZ	Jaffe EA <i>et al.</i> Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc. Natl. Acad. Sci., USA, 1983. Feb; 80(4):998-1002.	
BA	Prowse CV <i>et al.</i> A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb. Haemost., 1984. Feb 28; 51(1):110-114. (Abstract only)	
BB	Mumby SM <i>et al.</i> Interactions of thrombospondin with extracellular matrix proteins: selective binding to type V collagen. J. Cell Biol., 1984. 98(2): 646-652. (Abstract only)	
BC	Coligan, JE and Slayter HS. Structure of thrombospondin. J. Biol. Chem., 1984. 259:3944-3948.	
BD	Dixit VM <i>et al.</i> Isolation and characterization of a heparin-binding domain from the amino terminus of platelet thrombospondin. J Biol Chem, 1984. 259:10100-10105. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	3	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	BE	Lane DA <i>et al.</i> Detection of enhanced in vivo platelet alpha-granule release in different patient groups—comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays. <i>Thromb. Haemost.</i> , 1984. Oct 31; 52(2):183-187. (Abstract only)	
	BF	Lahav J <i>et al.</i> Thrombospondin interactions with fibronectin and fibrinogen. Mutual inhibition in binding. <i>Eur. J. Biochem.</i> , 1984. Nov 15; 145(1):151-156. (Abstract only)	
	BG	Silverstein RL <i>et al.</i> Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. <i>J. Clin. Invest.</i> , 1984. Nov; 74(5):1625-1633. (Abstract only)	
	BH	Lawler J <i>et al.</i> The structure of human platelet thrombospondin. <i>J. Biol. Chem.</i> , 1985. 260:3762-3772.	
	BI	Roberts DD <i>et al.</i> Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. <i>Nature</i> , 1985. 318(6041):64-66. (Abstract only)	
	BJ	Jaffe EA <i>et al.</i> Monocytes and macrophages synthesize and secrete thrombospondin. <i>Blood</i> , 1985. Jan; 65(1):79-84. (Abstract only)	
	BK	Dixit VM <i>et al.</i> Effects of anti-thrombospondin monoclonal antibodies on the agglutination of erythrocytes and fixed, activated platelets by purified thrombospondin. <i>Biochemistry</i> , 1985. Jul 30; 24(16):4270-4275.	
	BL	Silverstein RL <i>et al.</i> Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. <i>J. Biol. Chem.</i> , 1985. 260(18):10346-10352.	
	BM	Galvin NJ <i>et al.</i> Mapping of epitopes for monoclonal antibodies against human platelet thrombospondin with electron microscopy and high sensitivity amino acid sequencing. <i>J. Cell Biol.</i> , 1985. 101(4):1434-1441.	
	BN	Trzeciak MC <i>et al.</i> Plasma thrombospondin in patients with chronic renal failure, liver disease and splenectomy. <i>Thromb. Res.</i> , 1985. Oct 1; 40(1):121-128. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	4	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	BO	Tuszynski GP <i>et al.</i> The interaction of human platelet thrombospondin with fibrinogen. Thrombospondin purification and specificity of interaction. J. Biol. Chem., 1985. 260(22):12240-12245.	
	BP	Miller WR <i>et al.</i> Platelet-associated proteins in human breast cyst fluids. Clin. Chim. Acta, 1985. Oct 31; 152(1-2):37-42. (Abstract only)	
	BQ	Switalska HI <i>et al.</i> Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and beta-thromboglobulin antigen secretion and clearance from the circulation. J. Lab. Clin. Med., 1985. Dec; 106(6):690-700. (Abstract only)	
	BR	Kaplan KL <i>et al.</i> Plasma levels of platelet secretory proteins. Crit. Rev. Oncol. Hematol., 1986. 5(3):235-255. (Abstract only)	
	BS	Dixit VM <i>et al.</i> Monoclonal antibodies that recognize calcium-dependent structures of human thrombospondin. Characterization and mapping of their epitopes. J. Biol. Chem., 1986, 261(4):1962-1968.	
	BT	Wolff R <i>et al.</i> Interaction of thrombospondin with resting and stimulated human platelets. J. Biol. Chem., 1986. 261(15):6840-6846.	
	BU	Kao KJ <i>et al.</i> A monoclonal antibody-based enzyme-linked immunosorbent assay for quantitation of plasma thrombospondin. Am. J. Clin. Pathol., 1986. Sep; 86(3):317-323. (Abstract only)	
	BV	Lawler, J., <i>et al.</i> Thrombin and chymotrypsin interactions with thrombospondin. Ann N Y Acad. Sci. 1986; 485:273-87.	
	BW	Tuszynski GP <i>et al.</i> Methods of studying platelet-secreted proteins and the platelet cytoskeleton, Alan R. Liss, Inc., New York, 1987. 4:267-286.	
	BX	Frazier WA. Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cell. J. Cell Biol., 1987. 105(2):625-632.	
	BY	Asch AS <i>et al.</i> Isolation of the thrombospondin membrane receptor. J. Clin. Invest., 1987. Apr; 79:1054-1076. (Abstract only)	
	BZ	Galvin NJ <i>et al.</i> Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J. Cell Biol., 1987. 104(5):1413-1422. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	5	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	CA	Dardik R <i>et al.</i> The structure of endothelial cell thrombospondin. Characterization of the heparin-binding domains. Eur. J. Biochem., 1987. Oct 15; 168(2):347-355. (Abstract only)	
	CB	McCrohan MB <i>et al.</i> Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis. Thromb. Haemost., 1987. Oct 28; 58(3):850-852. (Abstract only)	
	CC	Walz, DA, <i>et al.</i> , Binding of thrombospondin to immobilized ligands: specific interaction with fibrinogen, plasminogen, histidine-rich glycoprotein, and fibronectin, Semin Throm Hemost. 13(3):317-325 1987.	
	CD	Legrand C <i>et al.</i> Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur. J. Biochem., 1988. Jan 15; 171(1-2):393-399. (Abstract only)	
	CE	Majack RA <i>et al.</i> Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation. J. Cell Biol. 1988. Feb.; 106: 415-422.	
	CF	Dawes J <i>et al.</i> Do extra-platelet sources contribute to the plasma level of thrombospondin? Thromb. Haemost., 1988. Apr 8; 59(2):273-276. (Abstract only)	
	CG	Clezardin P <i>et al.</i> Complex formation of human thrombospondin with osteonectin. Eur. J. Biochem., 1988. Aug 1; 175:275-284. (Abstract only)	
	CH	Asch AS and Nachman RL. Thrombospondin: phenomenology to function. Prog. Hemost. Thromb., 1989. 9:157-176. (Abstract only)	
	CI	Gehron-Robey P <i>et al.</i> Thrombospondin is an osteoblast-derived component of mineralized extracellular matrix. J. Cell Biol., 1989. 108:719-727.	
	CJ	Cardin AD and Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis, 1989. Jan-Feb; 9(1):21-32. (Abstract only)	
	CK	Bacon-Baguley T <i>et al.</i> Thrombospondin binding to specific sequences within the A α - and B β -chains of fibrinogen. J. Biol. Chem., 1990. 265(4):2317-23.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/525,610
				Filing Date	March 24, 2006
				First Named Inventor	Kevin J. Williams
				Group Art Unit	1643
				Examiner Name	Alana M. Harris
				Attorney Docket Number Customer No.	W1107/20010 03000
Sheet	6	of	13		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	--	---

	CL	Silverstein RL <i>et al.</i> Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. J. Biol. Chem., 1990. 265(19):11289-11294. (Abstract only)	
	CM	Good DJ <i>et al.</i> A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci., USA, 1990. Sep; 87:6624-6628.	
	CN	Gawaz MP <i>et al.</i> Effects of hemodialysis on platelet-derived thrombospondin. Kidney Int., 1991. Aug; 40(2):257-265. (Abstract only)	
	CO	Dardik R <i>et al.</i> Cell-binding domain of endothelial cell thrombospondin: localization to the 70kDa core fragment and determination of binding characteristics. Biochemistry, 1991. Sep 24; 30(38):9378-9386.	
	CP	Sage EH and Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J. Biol. Chem., 1991. 266(23):14831-14834.	
	CQ	Frazier WA. Thrombospondins. Current. Opin. Cell Biol., 1991. 3(5): 792-799. (Abstract only)	
	CR	Tuszynski GP <i>et al.</i> Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins. J. Cell Biol., 1992. 116(1):209-217.	
	CS	Lawler J <i>et al.</i> Expression and mutagenesis of thrombospondin. Biochemistry, 1992. Feb 4; 31(4):1173-1180.	
	CT	Prater CA <i>et al.</i> The properdin-like type I repeats of human thrombospondin contain a cell attachment site. J. Cell Biol., 1991. 112(5):1031-1040.	
	CU	Osterhout DJ <i>et al.</i> Thrombospondin promotes process outgrowth in neurons from the peripheral and central nervous systems. Devel. Biol, 1992. 150(2):256-265. (Abstract only)	
	CV	Tuszynski GP <i>et al.</i> Thrombospondin levels in patients with malignancy. Thromb. Haemost., 1992. 67(6):607-611. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	7	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	CW	Kosfeld MD <i>et al.</i> Identification of active peptide sequences in the carboxyl-terminal cell binding domain of human thrombospondin-1. J. Biol. Chem., 1992. 267(23):16230-16236.	
	CX	Zafar RS <i>et al.</i> Localization of two binding domains for thrombospondin within fibronectin. Arch. Biochem. Biophys., 1992. Sep; 297(2):271-276. (Abstract only)	
	CY	Soga T <i>et al.</i> Analysis of adhesive proteins on the surface of platelets from the patients with lung cancer: studies in histological type and clinical stage. Rinsho Ketsueki, 1992. Sep; 33(9):1121-1127. [Article in Japanese] (English Abstract only)	
	CZ	Takagi T <i>et al.</i> A single chain 19-kDa fragment from bovine thrombospondin binds to type V collagen and heparin. J. Biol. Chem., 1993. 268(21):15544-15549.	
	DA	Murphy-Ullrich JE <i>et al.</i> Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J. Biol. Chem., 1993. 268(35): 26784-26789. (Abstract only)	
	DB	Lawler J <i>et al.</i> Identification and characterization of thrombospondin-4, a new member of the thrombospondin gene family. J. Cell Biol., 1993. 120(4):1059-1067.	
	DC	Sipes JM <i>et al.</i> Inhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin. J. Cell Biol., 1993. 121(2):469-477.	
	DD	Tolsma <i>et al.</i> Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol., 1993. 122(2):497-511.	
	DE	Huang SW <i>et al.</i> The relationship between plasma thrombospondin level and the clinical course of atopic dermatitis. Allergy Proc., 1993. Sep-Oct; 14(5):357-361. (Abstract only)	
	DF	Zammit A <i>et al.</i> Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb. Haemost., 1993. Dec 20; 70(6):951-958. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	8	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	DG	Morandi V <i>et al.</i> Characterization of a novel monoclonal antibody (V58A4) raised against a recombinant NH2-terminal heparin-binding fragment of human endothelial cell thrombospondin. FEBS Lett, 1994. 346(2-3):156-160. (Abstract only)	
	DH	Bayraktar M. <i>et al.</i> Platelet Factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes melitus patients. J. Int. Med. Res., 1994, Mar-Apr; 22(2):90-94. (Abstract only)	
	DI	Nathan FE <i>et al.</i> Plasma thrombospondin levels in patients with gynecological malignancies. Cancer, 1994. Jun 1; 73(11):2853-2858. (Abstract only)	
	DJ	Shen D <i>et al.</i> Effects of hypoxia on platelet activation in pilots. Aviat Space Environ. Med., 1994. Jul; 65(7):646-648. (Abstract only)	
	DK	Schultz-Cherry S <i>et al.</i> The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J. Biol. Chem., 1994. 269(43): 26783-26788.	
	DL	Adams, JC, <i>et al.</i> The Thrombospondin Gene Family, Springer-Verlag: New York, 1995, pp.1-9, 11-56.	
	DM	Huang SW <i>et al.</i> Plasma thrombospondin levels in sheep with allergic asthma. Chest, 1996. Jun; 109(6):1614-1617.	
	DN	Qian X <i>et al.</i> Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc. Soc. Exp. Biol. Med., 1996. Jul; 212(3):199-207.	
	DO	Levine DM and William KJ. Automated measurement of mouse apolipoprotein B: convenient screening tool for mouse models of atherosclerosis. Clin. Chem., 1997. 43(4):669-674. (Abstract only)	
	DP	Partin AW <i>et al.</i> Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 1997. 277(18):1445-1451. (Abstract only)	
	DQ	Yamashita Y <i>et al.</i> Plasma thrombospondin levels in patients with colorectal carcinoma. Cancer, 1998. Feb 15; 82(4):632-638. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	9	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	DR	Goundis D <i>et al.</i> Properdin, the terminal complement components, thrombospondin and the circumsporozoite protein of malaria parasites contain similar sequence motifs. <i>Nature</i> , 1988. Sep 1; 335(6185):82-5. (Abstract only)	
	DS	Ozatli D <i>et al.</i> Circulating thrombomodulin, thrombospondin, and fibronectin in acute myeloblastic leukemias. <i>Haematologia (Budap.)</i> , 1999. 29(4):277-283. (Abstract only)	
	DT	Kanda S <i>et al.</i> Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. <i>Exp. Cell Res.</i> , 1999. 252(2):262-272.	
	DU	Panetti TS <i>et al.</i> Interaction of recombinant procollagen and properdin modules of thrombospondin-1 with heparin and fibrinogen/fibrin. <i>J. Biol. Chem.</i> , 1999. 274(1):430-437.	
	DV	Stancik R <i>et al.</i> Plasma levels of TPA, PAI-1 and thrombospondin in patients with systemic vasculitis. <i>Clin. Appl. Thromb. Hemost.</i> , 1999. Apr; 5(2):140-141.	
	DW	Roth JJ <i>et al.</i> Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-cycline receptor in fetal wounds. <i>Ann. Plast. Surg.</i> , 1999. May; 42(5):553-563. (Abstract only)	
	DX	Altun B <i>et al.</i> Thrombopoietin and thrombospondin in renal allograft recipients. <i>Blood Coagul. Fibrinolysis</i> , 1999. Jul; 10(5):233-237. (Abstract only)	
	DY	Krutzsch HC <i>et al.</i> Identification of an $\alpha(3)\beta(1)$ integrin recognition sequence in thrombospondin-1. <i>J. Biol. Chem.</i> , 1999. 274(34):24080-24086.	
	DZ	Nomura S <i>et al.</i> Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies. <i>Thromb. Res.</i> , 1999. Sep 1; 95:205-213.	
	EA	Michelson AD and Furman MI. Laboratory markers of platelet activation and their clinical significance. <i>Curr. Opin. Hematol.</i> , 1999. Sep; 6(5):342-348.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known		
				Application Number	10/525,610	
				Filing Date	March 24, 2006	
				First Named Inventor	Kevin J. Williams	
				Group Art Unit	1643	
				Examiner Name	Alana M. Harris	
				Attorney Docket Number Customer No.	W1107/20010 03000	
Sheet	10	of	13			
OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T

	EB	Chen et al. Cartilage oligomeric matrix protein is a calcium-binding protein, and a mutation in its type 3 repeats causes conformational changes. J. Biol. Chem., 2000. 275(34):26538-26544.	
	EC	Voland C <i>et al.</i> Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1. J. Bone Miner. Res., 2000. Feb; 15(2):361-368. (Abstract only)	
	ED	Carron JA <i>et al.</i> A CD36-binding peptide from thrombospondin-1 can stimulate resorption by osteoclasts in vitro. Biochem. Biophys. Res. Commun., 2000. Apr 21; 270(3):1124-1127. (Abstract only)	
	EE	Hayden K <i>et al.</i> Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application. Ann. Clin. Biochem., 2000. May; 37 (Pt. 3):319-325.	
	EF	Bergseth G <i>et al.</i> A novel enzyme immunoassay for plasma thrombospondin. Comparison with beta-thromboglobulin as platelet activation marker in vitro and in vivo. Thromb. Res., 2000. Jul 1; 99:41-50.	
	EG	Pini A and Bracci L. Phage display of antibody fragments. Curr. Protein Pept.Sci., 2000.Sep; 1(2):155-169. (Abstract only)	
	EH	Rusnati M <i>et al.</i> Thrombospondin-1/HIV-1 TAT protein interaction: modulation of the biological activity of extracellular TAT. FASEB J. 2000. Oct; 14:1917-1930.	
	EI	Vanguri, VK., <i>et al.</i> Thrombospondin-1 binds to polyhistidine with high affinity and specificity, Biochemical Society. 2000.	
	EJ	Bonnefoy A <i>et al.</i> A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen and GPIIb/IIIa receptor. J. Biol. Chem., 2001. 276(8):5605-5612.	
	EK	Damas C <i>et al.</i> The 33-kDa platelet alpha-granule membrane protein (GMP-33) is an N-terminal proteolytic fragment of thrombospondin. Thromb. Haemost. Sep;86(3):887-893. (Abstract only)	
	EL	Fraipont F <i>et al.</i> Thrombospondins and tumor angiogenesis. Trend Mol. Med., 2001. 7:401-407.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/525,610
				Filing Date	March 24, 2006
				First Named Inventor	Kevin J. Williams
				Group Art Unit	1643
				Examiner Name	Alana M. Harris
				Attorney Docket Number Customer No.	W1107/20010 03000
Sheet	11	of	13		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	---	---

	EM	Hofsteenge J <i>et al.</i> C-mannosylation and O-fucosylation of the thrombospondin type 1 module. J. Biol. Chem., 2001. 276(9):6485-6498.	
	EN	Hamaguchi N <i>et al.</i> Aptamer beacons for the direct detection of proteins. Anal. Biochem., 2001. Jul 15; 294(2):126-131. (Abstract only)	
	EO	Nomura S <i>et al.</i> Function and clinical significance of platelet-derived microparticles. Int. J. Hematol., 2001. Dec; 74(4):397-404. (Abstract only)	
	EP	Simantov, R., <i>et al.</i> Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1, J. Clin. Investig., January 2001, 107(1):45-52.	
	EQ	Qian MD <i>et al.</i> Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a recombinant phage display library. Hum. Antibodies, 2002. 11(3):97-105. (Abstract only)	
	ER	Zhang W <i>et al.</i> Production and characterization of human monoclonal anti-idiotypic antibodies to anti-dsDNA antibodies. Lupus, 2002. 11(6):362-369. (Abstract only)	
	ES	Asvadi P <i>et al.</i> Expression and functional analysis of recombinant scFV and diabody fragments with specificity for human RhD. J. Mol. Recognit., 2002. 15:321-330. (Abstract only)	
	ET	Rau D <i>et al.</i> Single-chain Fv antibody-alkaline phosphatase fusion proteins produced by one-step cloning as rapid detection tools for ELISA. J. Immunoassay Immunochem., 2002. 23(2):129-143. (Abstract only)	
	EU	Flores-Flores C <i>et al.</i> Development of human antibody fragments directed towards synaptic acetylcholinesterase using a semi-synthetic phage display library. J. Neural. Transm. Suppl., 2002. 62:165-179. (Abstract only)	
	EV	Stamey TA <i>et al.</i> Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urology, 2002. Jan; 167(1):103-111. (Abstract only)	
	EW	Baglia FA <i>et al.</i> Factor XI binding to the glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J.Biol. Chem., 2002. 277(3):1662-8.	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/525,610
				Filing Date	March 24, 2006
				First Named Inventor	Kevin J. Williams
				Group Art Unit	1643
				Examiner Name	Alana M. Harris
				Attorney Docket Number Customer No.	W1107/20010 03000
Sheet	12	of	13		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	---	---

	EX	Rau D <i>et al.</i> Cloning, functional expression and kinetic characterization of pesticide-selective Fab fragment variants derived by molecular evolution of variable antibody genes. Anal. Bioanal. Chem., 2002. Jan; 372(2):261-267. (Abstract only)	
	EY	Nathan S <i>et al.</i> Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin. J. Biochem. Mol. Biol. Biophys., 2002. Feb; 6(1):45-53. (Abstract only)	
	EZ	Baek H <i>et al.</i> An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucleic Acids Res., 2002. 30(5):e18.	
	FA	Zhou B <i>et al.</i> Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc. Natl. Acad. Sci., USA, 2002. Apr 16;99(8):5241-5246. (Abstract only)	
	FB	Gurney D <i>et al.</i> A reliable plasma marker of platelet activation: Does it exist? Am. J. Hematol., 2002. Jun; 70(2):139-144. (Abstract only)	
	FC	Reich N <i>et al.</i> Generation and characterization of human monoclonal scFv antibodies against Helicobacter pylori antigens. Infect. Immun., 2002. Aug; 70(8):4158-4164.	
	FD	O'Connell D <i>et al.</i> Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Mol. Biol., 2002. Aug 2; 321(1):49-56. (Abstract only)	
	FE	Lu D <i>et al.</i> Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J. Immunol. Methods, 2002. Sep 15; 267(2):213-226. (Abstract only)	
	FF	Oelschlaeger P <i>et al.</i> Fluorophor-linked immunosorbent assay: a time- and cost-saving method for the characterization of antibody fragments using a fusion protein of a single-chain antibody fragment and enhanced green fluorescent protein. Anal. Biochem, 2002. Oct 1; 309(1):27-34. (Abstract only)	

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheet as necessary)				Complete if Known	
				Application Number	10/525,610
				Filing Date	March 24, 2006
				First Named Inventor	Kevin J. Williams
				Group Art Unit	1643
				Examiner Name	Alana M. Harris
				Attorney Docket Number Customer No.	W1107/20010 03000
Sheet	13	of	13		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
-----------------------	-------------	--	---

	FG	Gao C <i>et al.</i> A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Natl. Acad. Sci., USA, 2002. Oct 1; 99(20):12612-12616. (Abstract only)	
	FH	Lee KJ <i>et al.</i> Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen. J. Am. Chem. Soc., 2002. Oct 23; 124(42):12439-12446. (Abstract only)	
	FI	Sinacola JR and Robinson AS. Rapid folding and polishing of single-chain antibodies from Escherichia coli inclusion bodies. Protein Expr. Purif., 2002. Nov; 26(2):301-308. (Abstract only)	
	FJ	Epel M <i>et al.</i> A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunol. Immunother., 2002. 51(10):565-573. (Abstract only)	
	FK	Schlattner U <i>et al.</i> Isoenzyme-directed selection and characterization of anti-creatine kinase single chain Fv antibodies from a human phage display library. Biochem. Biophys. Acta, 2002. Dec 12; 1579(2-3):124-132. (Abstract only)	
EXAMINER		DATE CONSIDERED	
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			